Use of Fecal Immunochemical Testing for Risk Stratification of Patients With Symptoms of Colorectal Cancer Referred for Diagnostic Colonoscopy
Year: 2024
Type: article
Abstract: Fecal immunochemical testing (FIT) is widely used in colorectal cancer (CRC) screening among asymptomatic individuals across many countries with varying cutoff values to select patients for colonoscopy.1 However, the implementation of FIT in symptomatic primary care patients is less prevalent among countries, most likely due to concerns about missed cancer diagnoses in these patients.2 The United Kingdom has now implemented FIT with a threshold of 10 μg hemoglobin (Hb)/g to risk-stratify symptomatic patients for their urgent cancer pathway (UCP).
Source: Gastroenterology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,180
Funders: Dagmar Marshalls Fond, Vissing Fonden, A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal, Helsefonden, Kai Lange og Gunhild Kai Langes Fond, Læge Sophus Carl Emil Friis og hustru Olga Doris Friis' Legat, Henrik Henriksens Fond, Oda og Hans Svenningsens Fond, Else og Mogens Wedell Wedellsborgs Fond, Familien Erichsens Mindefond
OpenAlex ID: W4405338417